Abstract
A once often neglected virus from common practice has been demanding the attention of all researchers for the past decade ever since it started to infect humans from its usual wild habitats. The severe acute respiratory syndrome coronavirus 2 infection in humans is now found to have frequent manifestations of thromboembolic events as a result of a hyper-coagulable state. Anti-coagulants (ACs) have been suggested to overcome such a state, and studies have been conducted to assess its role. The objective of this meta-analysis is to determine the existence of such a role and its nature, either beneficial or not, and to assess the strength of this role if it exists. We have conducted an online search in the databases such as PubMed, Google scholar, Lancet, Elsevier, JAMA, Medline, and so on and concluded ten studies among 2562 that had results which were more precise and of better quality. The results of six studies favored the use of ACs, whereas one study showed no beneficial response and four studies discussed the effects of therapeutic versus prophylactic anti-coagulation. The result of our statistical analysis was that the odds ratio for mortality reduction of ACs in coronavirus disease 2019 (COVID-19) patients is 0.6757 (95% CI; 0.5148 to 0.961) and that for benefits of therapeutic ACs versus prophylactic ACs in COVID-19 patients is 0.809 (95% CI; 0.6137 to 1.1917). AC was associated with lower mortality and intubation among hospitalised COVID-19 patients. Compared with therapeutic AC, prophylactic AC was associated with lower mortality, although not statistically significant, and lower bleeding risks.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have